Navigation Links
One Pill Might Prevent Heart Disease
Date:3/30/2009

Study finds five drugs in one dose reduced heart attack, stroke risk

MONDAY, March 30 (HealthDay News) -- Create a single pill that contains a statin, three blood pressure drugs and aspirin, and you have an inexpensive medication that can reduce the risk of heart attack, stroke and other cardiovascular problems.

Or so researchers hope.

A first trial of the polypill (which already has a brand name, Polycap), has been successful, according to a report that was to be presented Monday at the American College of Cardiology annual meeting in Orlando, Fla., and online in The Lancet.

The polypill contains generic versions of the blood pressure medications atenolol, hydrochlorothiazide and rampiril, as well as simvastatin (Zocor) and aspirin. It is designed to attack three major risk factors of cardiovascular disease -- high blood pressure, high blood cholesterol and formation of artery-blocking blood clots. It is being tested by an Indian company, Cadila Pharma.

The idea was originated by a group of physicians trained in India and now at McMaster University in Canada, said Dr. Koon Teo, a professor of medicine at McMaster and a member of the research team.

"We know that there are many medications that are beneficial," Teo said. "But often people don't like to take many pills, and doctors don't give patients all the pills they might need."

The first trial enrolled 2,053 people with one risk factor, such as high blood pressure, but no cardiovascular disease. They were divided into nine groups, one taking the polypill, the others various combinations of the medications.

The study, done at 50 centers in India, was designed to answer several questions:

Would the five-drug polypill deliver the same effect as individual pills? What reduction in blood pressure and cholesterol could it achieve? Would there be harmful interactions between the ingredients? Would aspirin reduce the blood-pressure-lowering effect?

The answers were favorable. The polypill reduced systolic blood pressure (the higher of the 120/80 reading) by 7.4 points and diastolic blood pressure by 5.6 points, better than the reduction produced by individual medications. LDL cholesterol reductions were almost as great as those produced by individual doses of simvastatin, the statin in the polypill. Readings showed a reduction in urinary levels of a clot-associated molecule. There was no indication of harmful interactions for those taking the polypill.

The blood pressure reduction caused by the polypill would lower the risk of heart disease by 24 percent and lower stroke risk by 33 percent, the researchers estimated. The cholesterol-lowering effect would reduce heart disease risk by 27 percent and stroke risk by 8 percent, they estimated.

And putting those benefits into one pill would increase the possibility that healthy people would actually take the medications needed to keep them healthy, they said.

"I think this is a good idea, in that even though all these drugs are available in separate pills, people don't take them for lots of reasons -- logistics, costs, availability," said Dr. Christopher P. Cannon, an associate professor of medicine at Harvard Medical School, who wrote an accompanying commentary in The Lancet. "If one had a simple, inexpensive pill, it could open cardiovascular protection to many people."

Millions of Americans who are at risk of cardiovascular disease because of common conditions, such as obesity and high blood pressure, are potential beneficiaries of a polypill, Cannon said. "They should be taking cardiovascular medications, but don't, because they are otherwise healthy," he said. "If there were one, simple pill, they might be open to taking it."

More studies obviously are needed, Cannon said, and physician care would be necessary if the pill became available. "You can't just give it and walk away," he said. "You would have to monitor for side effects, but once you get past that hurdle, one simple pill would help."

Some major regulatory changes by the U.S. Food and Drug Administration would be necessary for the polypill to be available in the United States, Cannon added. "The current mandates of the FDA are that a combination pill would have to be tested for every combination of every drug included in that pill. That obviously would not be feasible in this case. It would require a re-looking at the rules by the FDA, and for that, one needs larger and longer studies."

Even with those hurdles to overcome, a polypill would be "a major step forward in trying to simplify and broaden the applicability of all the medications that reduce cardiovascular risk," Cannon said.

The next step would be a major trial of the polypill among people with clear risk of cardiovascular disease, Teo said. If such a trial succeeded, the hope is that a drug company would pick up the idea, he said.

"The concept is important, and we are testing the concept," Teo said. "Once the concept is proved, we hope that a company in Europe or the United States could see that something can be done with it."

More information

Cardiovascular risk factors (including unavoidable ones such as aging) are listed by the American Heart Association.



SOURCES: Christopher P. Cannon, M.D., associate professor, medicine, Harvard Medical School, Boston; Koon Teo, M.D., professor, medicine, McMaster University, Hamilton, Ontario, Canada; March 30, 2009, Lancet; March 30, 2009, presentation, American College of Cardiology annual meeting, Orlando, Fla.


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Statin Might Help Fight Blood Clots in Veins
2. Study helps identify college drinkers who might continue excessive drinking as adults
3. 3 Steps Might Help Stop MRSAs Spread
4. Brain Hemorrhage Might Explain Natasha Richardsons Death
5. 6.5 million more patients might benefit from statins to prevent heart attacks, strokes
6. Narcolepsy Drug Might Be Addictive
7. Hormone Might Help Restore Female Fertility
8. Combo of Tests Might Spot Ovarian Cancer Early
9. Sunburn Might Play a Role in Rosacea
10. Technique Might Prevent Some Bladder Removals
11. New staging technique might save bladders in some bladder cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
One Pill Might Prevent Heart Disease
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... are derived from a cluster of melanin when exposed to sunlight. Although most moles ... a lifetime of embarrassment. Historically, mole removal has involved a painful, often ...
(Date:2/8/2016)... ... 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated ... his birthday on February 10th. During this time, people can achieve better health, ... 250,000 people from over 40 different countries as an “ordinary man with an extraordinary ...
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... , ... February 07, 2016 , ... Women's Excellence staff, ... Wear Red Day. National Wear Red Day is the first Friday each February ... disease and stroke cause 1 in 3 deaths among women each year – more ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Alzheimer Diagnostic Tests - Medical ... Medical Devices sector report , "Alzheimer Diagnostic Tests ... overview of Alzheimer Diagnostic Tests currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Aesthetic Devices ... GlobalData,s Medical Devices sector report, "Aesthetic Devices - Medical ... Devices currently in pipeline stage. This ... secondary and primary research by GlobalData,s team of industry ... be removed or altered based on the availability and ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology: